NO20061505L - Optalmiske preparater for behandling av okular hyperensjon - Google Patents

Optalmiske preparater for behandling av okular hyperensjon

Info

Publication number
NO20061505L
NO20061505L NO20061505A NO20061505A NO20061505L NO 20061505 L NO20061505 L NO 20061505L NO 20061505 A NO20061505 A NO 20061505A NO 20061505 A NO20061505 A NO 20061505A NO 20061505 L NO20061505 L NO 20061505L
Authority
NO
Norway
Prior art keywords
sub
treatment
sup
aryl
eye
Prior art date
Application number
NO20061505A
Other languages
English (en)
Norwegian (no)
Inventor
Meng Hsin Chen
James B Doherty
Luping Liu
Swaminathan R Natarajan
Robert M Tynebor
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20061505L publication Critical patent/NO20061505L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
    • C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20061505A 2003-09-04 2006-04-03 Optalmiske preparater for behandling av okular hyperensjon NO20061505L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50009503P 2003-09-04 2003-09-04
PCT/US2004/028266 WO2005026128A1 (en) 2003-09-04 2004-08-31 Ophthalmic compositions for treating ocular hypertension

Publications (1)

Publication Number Publication Date
NO20061505L true NO20061505L (no) 2006-04-27

Family

ID=34312181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061505A NO20061505L (no) 2003-09-04 2006-04-03 Optalmiske preparater for behandling av okular hyperensjon

Country Status (20)

Country Link
US (1) US7410992B2 (is)
EP (1) EP1663987B1 (is)
JP (1) JP4546961B2 (is)
KR (1) KR20060090801A (is)
CN (2) CN1845904A (is)
AT (1) ATE425971T1 (is)
AU (1) AU2004272546B2 (is)
BR (1) BRPI0414102A (is)
CA (1) CA2537410C (is)
DE (1) DE602004020079D1 (is)
EC (1) ECSP066404A (is)
IL (1) IL174068A0 (is)
IS (1) IS8306A (is)
MA (1) MA28017A1 (is)
MX (1) MXPA06002515A (is)
NO (1) NO20061505L (is)
NZ (1) NZ545401A (is)
RU (1) RU2006110625A (is)
WO (1) WO2005026128A1 (is)
ZA (1) ZA200601321B (is)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
KR20150058551A (ko) * 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
JP5325345B2 (ja) * 2010-10-08 2013-10-23 Ａｘｉｓ株式会社 線維筋痛症の診断剤
WO2012139495A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
CN110256314B (zh) * 2019-06-28 2020-12-15 南京林业大学 一种β-芳基酮类化合物的制备方法及其产品

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
AU3693789A (en) 1988-05-10 1989-11-29 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) New ophthalmic preparation for treating glaucoma
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1348437A3 (en) * 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
CA2164733A1 (en) 1993-06-08 1994-12-22 Nino Sorgente Methods and compositions for lowering intraocular pressure
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5573758A (en) * 1995-04-28 1996-11-12 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
US5925342A (en) * 1996-11-13 1999-07-20 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
PL356662A1 (en) 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
EP1251862B1 (en) * 2000-01-18 2008-10-01 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
NZ525164A (en) 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
CA2488802A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043354A2 (en) * 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
AU2004271978B2 (en) * 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension

Also Published As

Publication number Publication date
US20070010491A1 (en) 2007-01-11
CN102558231B (zh) 2015-05-27
NZ545401A (en) 2008-10-31
DE602004020079D1 (de) 2009-04-30
EP1663987B1 (en) 2009-03-18
WO2005026128A1 (en) 2005-03-24
CA2537410A1 (en) 2005-03-24
ECSP066404A (es) 2006-09-18
RU2006110625A (ru) 2006-08-10
AU2004272546B2 (en) 2007-10-18
MA28017A1 (fr) 2006-07-03
JP4546961B2 (ja) 2010-09-22
KR20060090801A (ko) 2006-08-16
IS8306A (is) 2006-02-16
EP1663987A1 (en) 2006-06-07
ATE425971T1 (de) 2009-04-15
IL174068A0 (en) 2006-08-01
AU2004272546A1 (en) 2005-03-24
CN102558231A (zh) 2012-07-11
JP2007504233A (ja) 2007-03-01
US7410992B2 (en) 2008-08-12
MXPA06002515A (es) 2006-06-20
CA2537410C (en) 2009-08-11
ZA200601321B (en) 2007-05-30
CN1845904A (zh) 2006-10-11
BRPI0414102A (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
DE60307607D1 (de) Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
BR0014596A (pt) Derivado de pirimidina, uso do mesmo, composição farmacêutica, e, método de tratar doenças ou condições médicas mediadas por citocinas
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
TW200740760A (en) Malonamide derivatives
WO2002009702A3 (en) Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension
TW200501949A (en) Ophthalmic compositions for treating ocular hypertension
SE0402925D0 (sv) Novel Compounds
DK0437030T3 (da) Anvendelse af 4-substituerede imidazoler til nedsættelse af det intraoculære tryk
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
DE60003435D1 (de) Neue 2-decarboxy-2-phosphinico prostaglandin f analoge
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
MA28017A1 (fr) Compositions ophtalmiques traitant l'hypertention oculaire
DE60135972D1 (de) Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
IL166103A0 (en) Pyrrolidine derivatives and their use
JP2016056207A (ja) プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法
CA2831025C (en) Pharmaceutical composition for preventing or treating macular degeneration
ATE511506T1 (de) Thiopen-derivate als wirkstoffe gegen okulare hypotonie
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension
DE602006014576D1 (de) Zur behandlung von mit trpv1 in zusammenhang stehenden erkrankungen geeignete 2-(benzimidazol-1yl)-n-(4-phenylthiazol-2-yl)acetamidderivate
WO2008030390A3 (en) Ophthalmic compositions for treating ocular hypertension